

[As Amended by Senate Committee of the Whole]

As Amended by Senate Committee

Session of 2008

SENATE BILL No. 629

By Committee on Financial Institutions and Insurance

2-15

12 AN ACT concerning insurance; relating to coverage for patient care serv-
13 ices in a cancer clinical trial; amending K.S.A. 2007 Supp. 40-2,103
14 and 40-19c09 and repealing the existing sections.
15

16 *Be it enacted by the Legislature of the State of Kansas:*

17 New Section 1. (a) As used in this section: (1) “Clinical trial” means
18 the controlled clinical testing in human subjects of investigational new
19 drugs, items, devices, services, treatments, diagnostics or comparisons of
20 approved drugs, items, devices, services, treatments or diagnostics, to
21 assess the safety, efficacy, benefits, costs, adverse reactions or outcomes,
22 or both, of such drugs, items, devices, services, treatments or diagnostics;

23 (2) “cooperative group” means a formal network of facilities that col-
24 laborate on research projects and have an established peer review pro-
25 gram, including, but not limited to, the national cancer institute clinical
26 cooperative group and the national cancer institute community clinical
27 oncology program;

28 (3) “individual” means a member, subscriber, insured or certificate
29 holder or a covered dependent policy holder, subscriber, insured or cer-
30 tificate holder; and

31 (4) (A) “patient care service” means medically necessary drugs, de-
32 vices, items, services, treatments or diagnostics that are provided to an
33 individual enrolled in a clinical trial, if such drugs, items, devices, services,
34 treatments or diagnostics would otherwise be covered under the individ-
35 ual’s health plan or insurance contract, if the individual was not enrolled
36 in a clinical trial. Such drugs, items, devices, services, treatments or di-
37 agnostics shall include the following:

38 (i) Health care services typically provided absent a clinical trial;

39 (ii) health care services required for the clinically appropriate moni-
40 toring of the investigational drug, item, device, service, treatment or
41 diagnostic;

42 (iii) health care services provided for the prevention of complications
43 arising from the provision of the investigational drug, item, device, serv-

1 ice, treatment or diagnostic; and
2 (iv) health care services needed for the reasonable and necessary care
3 arising from the provision of the investigational drug, item, device, serv-
4 ice, treatment or diagnostic, including the diagnosis or treatment of the
5 complications.
6 (B) “Patient care service” does not include the following:
7 (i) The cost of an investigational drug or device;
8 (ii) non-health care services, including, but not limited to, travel,
9 housing, companion expenses and other nonclinical expenses that a pa-
10 tient may be subjected to as a result of the treatment being provided for
11 purposes of the clinical trial;
12 (iii) services associated with managing the research associated with
13 the clinical trial; and
14 (iv) services that would not be covered under the patient’s policy,
15 plan, agreement or contract for noninvestigational treatments.
16 (b) Any policy, contract, agreement, plan or certificate of insurance
17 issued, delivered or renewed within the state shall provide coverage for
18 patient care services provided to an individual in a cancer clinical trial
19 that is a prevention, screening, early detection, treatment and survivorship
20 study for cancer for a pilot or feasibility trial or a phase I, phase II, phase
21 III or phase IV clinical trial; and has been peer reviewed and is approved
22 by the national institutes of health, a qualified nongovernmental research
23 entity identified in guidelines issued by the national institutes of health
24 cooperative group, the federal food and drug administration in the form
25 of an investigational new drug application, the United States department
26 of defense or veterans affairs or a qualified institutional review board
27 **[registered with the federal office for human research protections]**.
28 ~~(c) Coverage under this section shall be required if the cancer pro-~~
29 ~~gram conducting the clinical trial is capable of doing so by virtue of the~~
30 ~~experience and training of such facility and personnel and treats a suffi-~~
31 ~~cient volume of patients to maintain such expertise and maintains ac-~~
32 ~~creditation by the American college of surgeons commission on cancer.~~
33 ~~(c)~~ **[(c)]** Coverage under this section shall be subject to all other
34 terms and conditions of the policy, contract, agreement, plan or certificate
35 of insurance, including, but not limited to, provisions requiring the use
36 of participating providers and provisions related to utilization review. Pay-
37 ment to health care providers under this section shall be subject to the
38 terms and conditions of the applicable agreement between the provider
39 and the member, including, but not limited to, provisions relating to uti-
40 lization review, audits and the financial liability of covered persons.
41 ~~(d)~~ **[(d)]** Each such policy, contract, agreement, plan or certificate of
42 insurance shall provide written notice, as currently required, to all en-
43 rollees, insureds and subscribers regarding the coverage required by the

1 provisions of this section.

2 ~~(f)~~ [(e)] No such policy, contract, agreement, plan or certificate of
3 insurance shall deny to a patient eligibility, or continued eligibility, to
4 enroll or to renew coverage under terms of the policy, contract, agree-
5 ment, plan or certificate, solely for the purpose of avoiding the require-
6 ments of this section.

7 ~~(g)~~ [(f)] The provisions of this section shall not apply to any policy
8 or certificate which provides coverage for any specified disease, specified
9 accident or accident only coverage, credit, dental, disability income, hos-
10 pital indemnity, long-term care insurance as defined by K.S.A. 40-2227,
11 and amendments thereto, vision care or any other limited supplemental
12 benefit nor to any medicare supplement policy of insurance as defined
13 by the commissioner of insurance by rule and regulation, any coverage
14 issued as a supplement to liability insurance, workers' compensation or
15 similar insurance, automobile medical-payment insurance or any insur-
16 ance under which benefits are payable with or without regard to fault,
17 whether written on a group, blanket or individual basis.

18 ~~(h)~~ [(g)] Copayments and deductibles applied to services delivered
19 in a clinical trial shall be the same as those applied to the same services
20 if they were not delivered in a clinical trial.

21 ~~(i)~~ [(h)] The provision of services when required by this section shall
22 not, in itself, give rise to liability on the part of the health care service
23 plan.

24 ~~(j)~~ [(i)] Nothing in this section shall be construed to prohibit a plan,
25 policy, agreement or contract from restricting ~~coverage for clinical trials~~
26 **[the coverage required under subsection (b)]** to participating hospitals
27 and physicians in Kansas ~~unless the protocol for the clinical trial is not~~
28 ~~provided for at a Kansas hospital or by a Kansas physician.~~

29 ~~(k)~~ [(j)] The provisions of this section shall be applicable to the Kan-
30 sas state employees health care benefits program and municipal funded
31 pools.

32 ~~(l)~~ [(k)] The provisions of K.S.A. 40-2249a, and amendments thereto,
33 shall not apply to the provisions of this section.

34 ~~(m)~~ [(l)] The provisions of this section shall not apply to a policy,
35 plan or contract paid for under title XVIII or title XIX of the federal social
36 security act.

37 ~~(n)~~ [(m)] The provisions of this act shall apply to all policies, con-
38 tracts, agreements, plans or certificates of insurance issued or delivered
39 within the state on or after January 1, ~~2008~~ **2009**, and to all policies,
40 contracts, agreements, plans or certificates of insurance in effect before
41 January 1, ~~2008~~ **2009**, upon renewal or amendment, on or after January
42 1, ~~2008~~ **2009**.

43 Sec. 2. K.S.A. 2007 Supp. 40-2,103 is hereby amended to read as

1 follows: 40-2,103. The requirements of K.S.A. 40-2,100, 40-2,101, 40-
2 2,102, 40-2,104, 40-2,105, 40-2,114, 40-2,160, 40-2,165 through 40-2,170,
3 inclusive, 40-2250, K.S.A. 2007 Supp. 40-2,105a ~~and~~ 40-2,105b *and section*
4 *1*, and amendments thereto, shall apply to all insurance policies,
5 subscriber contracts or certificates of insurance delivered, renewed or
6 issued for delivery within or outside of this state or used within this state
7 by or for an individual who resides or is employed in this state.

8 Sec. 3. K.S.A. 2007 Supp. 40-19c09 is hereby amended to read as
9 follows: 40-19c09. (a) Corporations organized under the nonprofit med-
10 ical and hospital service corporation act shall be subject to the provisions
11 of the Kansas general corporation code, articles 60 to 74, inclusive, of
12 chapter 17 of the Kansas Statutes Annotated, applicable to nonprofit cor-
13 porations, to the provisions of K.S.A. 40-214, 40-215, 40-216, 40-218, 40-
14 219, 40-222, 40-223, 40-224, 40-225, 40-226, 40-229, 40-230, 40-231, 40-
15 235, 40-236, 40-237, 40-247, 40-248, 40-249, 40-250, 40-251, 40-252,
16 40-254, 40-2,100, 40-2,101, 40-2,102, 40-2,103, 40-2,104, 40-2,105, 40-
17 2,116, 40-2,117, 40-2,153, 40-2,154, 40-2,160, 40-2,161, 40-2,163 through
18 40-2,170, inclusive, 40-2a01 et seq., 40-2111 to 40-2116, inclusive, 40-
19 2215 to 40-2220, inclusive, 40-2221a, 40-2221b, 40-2229, 40-2230, 40-
20 2250, 40-2251, 40-2253, 40-2254, 40-2401 to 40-2421, inclusive, and 40-
21 3301 to 40-3313, inclusive, K.S.A. 2007 Supp. 40-2,105a ~~and~~ 40-2,105b
22 *and section 1*, and amendments thereto, except as the context otherwise
23 requires, and shall not be subject to any other provisions of the insurance
24 code except as expressly provided in this act.

25 (b) No policy, agreement, contract or certificate issued by a corpo-
26 ration to which this section applies shall contain a provision which ex-
27 cludes, limits or otherwise restricts coverage because medicaid benefits
28 as permitted by title XIX of the social security act of 1965 are or may be
29 available for the same accident or illness.

30 (c) Violation of subsection (b) shall be subject to the penalties pre-
31 scribed by K.S.A. 40-2407 and 40-2411, and amendments thereto.

32 ***New Sec. 4. (a) (1) There is hereby created a clinical trials cov-***
33 ***erage advisory committee which shall assess the economic impact***
34 ***of the health insurance coverage required by this act for patient***
35 ***care costs in clinical trials. In order to assess the costs and benefits***
36 ***of insurance coverage for patient care costs incurred in clinical tri-***
37 ***als, the advisory committee may request and collect from insurers***
38 ***aggregate clinical and financial data related to coverage for services***
39 ***provided pursuant to this act.***

40 ***(2) The clinical trials coverage advisory committee shall be at-***
41 ***tached to the insurance department. The insurance department***
42 ***shall provide staff and administrative support required by the ad-***
43 ***visory committee.***

- 1 ***(b) The advisory committee shall consist of nine members ap-***
2 ***pointed by the commissioner of insurance as follows:***
3 ***(1) Four persons, two of whom shall be medical directors of***
4 ***health insurers, selected from nominations made by the Kansas as-***
5 ***sociation of health plans;***
6 ***(2) one person representing the university of Kansas school of***
7 ***medicine nominated by the dean of such school;***
8 ***(3) one licensed physician who has experience in cancer treat-***
9 ***ment and clinical trials nominated by the Kansas medical society;***
10 ***(4) one person representing hospitals nominated by the Kansas***
11 ***hospital association;***
12 ***(5) one person representing the general public appointed by the***
13 ***commissioner of insurance; and***
14 ***(6) the commissioner of insurance or the commissioner's***
15 ***designee.***
16 ***(c) Each appointment to the clinical trials coverage advisory***
17 ***committee shall be for a term of three years.***
18 ***(d) The insurance commissioner or the commissioner's designee***
19 ***shall serve as chairperson of the clinical trials coverage advisory***
20 ***committee.***
21 ***(e) The clinical trials coverage advisory committee shall pre-***
22 ***pare a report of its findings and any recommendations for changes***
23 ***to this act to the chairs of the house committee on insurance and***
24 ***financial institutions and the senate financial institutions and in-***
25 ***surance committee on or before January 1, 2011.***
26 Sec. ~~4~~ **5.** K.S.A. 2007 Supp. 40-2,103 and 40-19c09 are hereby
27 repealed.
28 Sec. ~~5~~ **6.** This act shall take effect and be in force from and after its
29 publication in the statute book.